[1] |
ONG AML. Outrunning burnout in a GI fellowship program during the COVID-19 pandemic[J]. Dig Dis Sci, 2020, 65( 8): 2161- 2163. DOI: 10.1007/s10620-020-06401-4.
|
[2] |
KUDO M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2022, 11( 4): 592- 596. DOI: 10.21037/hbsn-22-143.
|
[3] |
LEE AJ, CHUN YS. Intrahepatic cholangiocarcinoma: The AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7( 5): 52. DOI: 10.21037/cco.2018.07.03.
|
[4] |
CARDINALE V, SEMERARO R, TORRICE A, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors[J]. World J Gastrointest Oncol, 2010, 2( 11): 407- 416. DOI: 10.4251/wjgo.v2.i11.407.
|
[5] |
WRONKA KM, GRĄT M, STYPUŁKOWSKI J, et al. Relevance of preoperative hyperbilirubinemia in patients undergoing hepatobiliary resection for hilar cholangiocarcinoma[J]. J Clin Med, 2019, 8( 4): 458. DOI: 10.3390/jcm8040458.
|
[6] |
VOGEL A, BRIDGEWATER J, EDELINE J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34( 2): 127- 140. DOI: 10.1016/j.annonc.2022.10.506.
|
[7] |
KELLEY RK, UENO M, YOO C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer(KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401( 10391): 1853- 1865. DOI: 10.1016/S0140-6736(23)00727-4.
|
[8] |
DUMONCEAU JM, TRINGALI A, PAPANIKOLAOU IS, et al. Endoscopic biliary stenting: Indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy(ESGE) Clinical Guideline-Updated October 2017[J]. Endoscopy, 2018, 50( 9): 910- 930. DOI: 10.1055/a-0659-9864.
|
[9] |
MANSOUR JC, ALOIA TA, CRANE CH, et al. Hilar cholangiocarcinoma: Expert consensus statement[J]. HPB, 2015, 17( 8): 691- 699. DOI: 10.1111/hpb.12450.
|
[10] |
UEMURA K, MURAKAMI Y, SATOI S, et al. Impact of preoperative biliary drainage on long-term survival in resected pancreatic ductal adenocarcinoma: A multicenter observational study[J]. Ann Surg Oncol, 2015, 22( Suppl 3): S1238- S1246. DOI: 10.1245/s10434-015-4618-9.
|
[11] |
STROM TJ, KLAPMAN JB, SPRINGETT GM, et al. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage[J]. Surg Endosc, 2015, 29( 11): 3273- 3281. DOI: 10.1007/s00464-015-4075-3.
|
[12] |
MIURA F, SANO K, WADA K, et al. Prognostic impact of type of preoperative biliary drainage in patients with distal cholangiocarcinoma[J]. Am J Surg, 2017, 214( 2): 256- 261. DOI: 10.1016/j.amjsurg.2017.01.010.
|
[13] |
TIEU AH, KUMBHARI V, JAKHETE N, et al. Diagnostic and therapeutic utility of SpyGlass(®) peroral cholangioscopy in intraductal biliary disease: Single-center, retrospective, cohort study[J]. Dig Endosc, 2015, 27( 4): 479- 485. DOI: 10.1111/den.12405.
|
[14] |
PEREIRA P, VILAS-BOAS F, PEIXOTO A, et al. How SpyGlass™ may impact endoscopic retrograde cholangiopancreatography practice and patient management[J]. GE Port J Gastroenterol, 2018, 25( 3): 132- 137. DOI: 10.1159/000481859.
|
[15] |
GÓMEZ-ESPAÑA MA, MONTES AF, GARCIA-CARBONERO R, et al. SEOM clinical guidelines for pancreatic and biliary tract cancer(2020)[J]. Clin Transl Oncol, 2021, 23( 5): 988- 1000. DOI: 10.1007/s12094-021-02573-1.
|
[16] |
GOERE D, WAGHOLIKAR GD, PESSAUX P, et al. Utility of staging laparoscopy in subsets of biliary cancers: Laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma[J]. Surg Endosc, 2006, 20( 5): 721- 725. DOI: 10.1007/s00464-005-0583-x.
|
[17] |
PRIMROSE JN, FOX RP, PALMER DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): A randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20( 5): 663- 673. DOI: 10.1016/S1470-2045(18)30915-X.
|
[18] |
BANALES JM, MARIN JJG, LAMARCA A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 9): 557- 588. DOI: 10.1038/s41575-020-0310-z.
|
[19] |
SOARES KC, KAMEL I, COSGROVE DP, et al. Hilar cholangiocarcinoma: Diagnosis, treatment options, and management[J]. Hepatobiliary Surg Nutr, 2014, 3( 1): 18- 34. DOI: 10.3978/j.issn.2304-3881.2014.02.05.
|
[20] |
BHUTIANI N, SCOGGINS CR, MCMASTERS KM, et al. The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: A multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. Surgery, 2018, 163( 4): 726- 731. DOI: 10.1016/j.surg.2017.10.028.
|
[21] |
WAHAB MA, SULTAN AM, SALAH T, et al. Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: Is it of value?[J]. Hepato-gastroenterology, 2012, 59( 114): 321- 324. DOI: 10.5754/hge11999.
|
[22] |
WEBER SM, RIBERO D, O’REILLY EM, et al. Intrahepatic cholangiocarcinoma: Expert consensus statement[J]. HPB, 2015, 17( 8): 669- 680. DOI: 10.1111/hpb.12441.
|
[23] |
HEIMBACH JK, GORES GJ, HADDOCK MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24( 2): 201- 207. DOI: 10.1055/s-2004-828896.
|
[24] |
BREUER E, MUELLER M, DOYLE MB, et al. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study[J]. Ann Surg, 2022, 276( 5): 846- 853. DOI: 10.1097/SLA.0000000000005641.
|
[25] |
ETHUN CG, LOPEZ-AGUIAR AG, ANDERSON DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: An argument for shifting treatment paradigms for resectable disease[J]. Ann Surg, 2018, 267( 5): 797- 805. DOI: 10.1097/SLA.0000000000002574.
|
[26] |
PARK JH, CHOI EK, AHN SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79( 3): 696- 704. DOI: 10.1016/j.ijrobp.2009.12.031.
|
[27] |
BORGHERO Y, CRANE CH, SZKLARUK J, et al. Extrahepatic bile duct adenocarcinoma: Patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone[J]. Ann Surg Oncol, 2008, 15( 11): 3147- 3156. DOI: 10.1245/s10434-008-9998-7.
|
[28] |
KIM TH, HAN SS, PARK SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81( 5): e853- e859. DOI: 10.1016/j.ijrobp.2010.12.019.
|
[29] |
LIM KH, OH DY, CHIE EK, et al. Adjuvant concurrent chemoradiation therapy(CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer: A non-randomized, single center study[J]. BMC Cancer, 2009, 9: 345. DOI: 10.1186/1471-2407-9-345.
|
[30] |
NELSON JW, GHAFOORI AP, WILLETT CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 73( 1): 148- 153. DOI: 10.1016/j.ijrobp.2008.07.008.
|
[31] |
HUGHES MA, FRASSICA DA, YEO CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct[J]. Int J Radiat Oncol Biol Phys, 2007, 68( 1): 178- 182. DOI: 10.1016/j.ijrobp.2006.11.048.
|
[32] |
BEN-JOSEF E, GUTHRIE KA, EL-KHOUEIRY AB, et al. SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015, 33( 24): 2617- 2622. DOI: 10.1200/JCO.2014.60.2219.
|
[33] |
HAWKINS WG, DEMATTEO RP, JARNAGIN WR, et al. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer[J]. Ann Surg Oncol, 2004, 11( 3): 310- 315. DOI: 10.1245/aso.2004.03.011.
|
[34] |
DASARI BVM, IONESCU MI, PAWLIK TM, et al. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis[J]. J Surg Oncol, 2018, 118( 3): 477- 485. DOI: 10.1002/jso.25186.
|
[35] |
NISHIO H, EBATA T, YOKOYAMA Y, et al. Gallbladder cancer involving the extrahepatic bile duct is worthy of resection[J]. Ann Surg, 2011, 253( 5): 953- 960. DOI: 10.1097/SLA.0b013e318216f5f3.
|
[36] |
REGIMBEAU JM, FUKS D, BACHELLIER P, et al. Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group[J]. Eur J Surg Oncol, 2011, 37( 6): 505- 512. DOI: 10.1016/j.ejso.2011.03.135.
|
[37] |
ALOIA TA, JÁRUFE N, JAVLE M, et al. Gallbladder cancer: Expert consensus statement[J]. HPB, 2015, 17( 8): 681- 690. DOI: 10.1111/hpb.12444.
|
[38] |
FUKS D, REGIMBEAU JM, LE TREUT YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 Study Group[J]. World J Surg, 2011, 35( 8): 1887- 1897. DOI: 10.1007/s00268-011-1134-3.
|
[39] |
LEE SE, JANG JY, LIM CS, et al. Systematic review on the surgical treatment for T1 gallbladder cancer[J]. World J Gastroenterol, 2011, 17( 2): 174- 180. DOI: 10.3748/wjg.v17.i2.174.
|
[40] |
QADAN M, KINGHAM TP. Technical aspects of gallbladder cancer surgery[J]. Surg Clin North Am, 2016, 96( 2): 229- 245. DOI: 10.1016/j.suc.2015.12.007.
|
[41] |
RUFF SM, CLOYD JM, PAWLIK TM. Annals of surgical oncology practice guidelines series: Management of primary liver and biliary tract cancers[J]. Ann Surg Oncol, 2023, 30( 13): 7935- 7949. DOI: 10.1245/s10434-023-14255-z.
|